MX2020004620A - Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia. - Google Patents
Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.Info
- Publication number
- MX2020004620A MX2020004620A MX2020004620A MX2020004620A MX2020004620A MX 2020004620 A MX2020004620 A MX 2020004620A MX 2020004620 A MX2020004620 A MX 2020004620A MX 2020004620 A MX2020004620 A MX 2020004620A MX 2020004620 A MX2020004620 A MX 2020004620A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- surgery
- peptibodies
- analogs
- analogues
- Prior art date
Links
- 238000001356 surgical procedure Methods 0.000 title abstract 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 2
- 235000016236 parenteral nutrition Nutrition 0.000 abstract 2
- 238000002271 resection Methods 0.000 abstract 2
- 210000000813 small intestine Anatomy 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 235000015816 nutrient absorption Nutrition 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 abstract 1
- 229960002444 teduglutide Drugs 0.000 abstract 1
- 108010073046 teduglutide Proteins 0.000 abstract 1
- -1 teduglutide Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Análogos de GLP-2, tales como teduglutida, y proteínas de fusión de GLP-2 con inmunoglobulina se administraron antes, durante o después de la cirugía, particularmente la resección del intestino delgado. Cuando se desarrolla síndrome del intestino corto tras la resección quirúrgica del intestino delgado, es usualmente necesaria la nutrición parenteral para compensar la absorción reducida de agua y nutrientes a través del intestino delgado. Los análogos de GLP-2 y las proteínas de fusión de GLP-2 promueven el crecimiento del intestino delgado, mejoran la absorción de nutrientes y pueden reducir la necesidad de la nutrición parenteral tras la cirugía.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059175 WO2019090209A1 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004620A true MX2020004620A (es) | 2020-10-12 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004620A MX2020004620A (es) | 2017-11-06 | 2018-11-05 | Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (es) |
| EP (1) | EP3706774A4 (es) |
| JP (2) | JP7296958B2 (es) |
| KR (1) | KR20200085763A (es) |
| CN (1) | CN111629745A (es) |
| AR (1) | AR113835A1 (es) |
| AU (1) | AU2018360744A1 (es) |
| BR (1) | BR112020008936A2 (es) |
| CA (1) | CA3079523A1 (es) |
| IL (1) | IL274098B2 (es) |
| MX (1) | MX2020004620A (es) |
| TW (1) | TW201922279A (es) |
| WO (1) | WO2019090209A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019040399A1 (en) * | 2017-08-22 | 2019-02-28 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| PH12022550852A1 (en) | 2019-10-07 | 2023-05-03 | Kallyope Inc | Gpr119 agonists |
| EP4126003A1 (en) * | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| IL298306A (en) | 2020-05-19 | 2023-01-01 | Kallyope Inc | ampk operators |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| BRPI0615538A2 (pt) * | 2005-07-29 | 2011-05-17 | Amprotein Corp | proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição farmacêutica, composição alimentar, método para a redução do peso corpóreo, método para o tratamento de diabetes, método para aumentar a vida média de um peptìdio ou uma proteìna terapêutica recombinante em um indivìduo, método para aumentar a eficácia de um peptìdio ou proteìna terapêutica, método para o tratamento de diabetes ou redução do peso corpóreo |
| BRPI0617515A2 (pt) * | 2005-10-24 | 2011-07-26 | Centocor Inc | mimeticorpos, polipeptÍdeos, composiÇÕes, mÉtodos e usos de glp-2 |
| US7812121B2 (en) * | 2006-08-31 | 2010-10-12 | Baker Audrey E | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| JP2008247789A (ja) * | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| AU2012308636B2 (en) | 2011-09-12 | 2017-08-31 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| BR112014027345A2 (pt) | 2012-05-03 | 2019-09-03 | Zealand Pharma As | análogos de peptídeo 2 semelhante ao glucagon (glp-2) |
| WO2015095684A1 (en) * | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en unknown
- 2018-11-05 KR KR1020207013387A patent/KR20200085763A/ko not_active Application Discontinuation
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-06 TW TW107139266A patent/TW201922279A/zh unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP2023107883A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7296958B2 (ja) | 2023-06-23 |
| CN111629745A (zh) | 2020-09-04 |
| BR112020008936A2 (pt) | 2020-10-20 |
| IL274098B2 (en) | 2024-12-01 |
| RU2020118172A (ru) | 2021-12-08 |
| IL274098B1 (en) | 2024-08-01 |
| AU2018360744A1 (en) | 2020-05-07 |
| JP2021502389A (ja) | 2021-01-28 |
| EP3706774A4 (en) | 2021-09-08 |
| US20210169986A1 (en) | 2021-06-10 |
| TW201922279A (zh) | 2019-06-16 |
| IL274098A (en) | 2020-06-30 |
| CA3079523A1 (en) | 2019-05-09 |
| EP3706774A1 (en) | 2020-09-16 |
| AR113835A1 (es) | 2020-06-17 |
| KR20200085763A (ko) | 2020-07-15 |
| JP2023107883A (ja) | 2023-08-03 |
| WO2019090209A1 (en) | 2019-05-09 |
| US11660328B2 (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004620A (es) | Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia. | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| BR112015021446A2 (pt) | métodos cirúrgicos empregando composições de peptídeo amfifílico purificado | |
| AR103246A1 (es) | Derivados de fgf21 y sus usos | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| ECSP21093559A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| CO2022007273A2 (es) | Análogos de insulina novedosos y usos de estos | |
| AR111236A1 (es) | Uso intradialítico de tiosulfato de sodio | |
| CO2018000768A2 (es) | Administración intravenosa de citrulina durante la cirugía | |
| CL2020000310A1 (es) | Análogos de insulina acilados novedosos y usos de estos. | |
| BR112017019431A2 (pt) | material de implante de compósito | |
| EA201591910A1 (ru) | Стабильный раствор бромфенака | |
| EA201992436A1 (ru) | Композиции с улучшенной стабильностью и биодоступностью для введения (e)-2,6-диалкокси 4-замещенных бензилсульфонов | |
| AR115921A1 (es) | Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile | |
| AR102248A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| RU2018108842A (ru) | Способ лечения заболевания с использованием соединения, оказывающего воздействие на гликолиз | |
| PE20191462A1 (es) | Composicion liquida que contiene pradofloxacina | |
| MX2018001041A (es) | Concentrado que contiene alprostadil. | |
| BR112017006200A2 (pt) | dispositivos de fio de fita transósseo e um sistema e método para utilizar os dispositivos | |
| BR112016006145A2 (pt) | dispositivo de fixação externa para osteossíntese do ombro | |
| BR112012022203A2 (pt) | um promotor de secreção de imunoglobulina |